{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:49:21Z","timestamp":1791532161353,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018407","name":"Associazione Gian Franco Lupo \u201cUn Sorriso alla Vita\u201d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.06.041","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:59:42Z","timestamp":1782345582000},"page":"1212-1222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9185-724X","authenticated-orcid":false,"given":"Luisa","family":"Anelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-6200","authenticated-orcid":false,"given":"Cosimo","family":"Cumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-6661","authenticated-orcid":false,"given":"Antonella","family":"Zagaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Coccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Tota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-9245","authenticated-orcid":false,"given":"Maria Rosa","family":"Conserva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2015-635X","authenticated-orcid":false,"given":"Immacolata","family":"Redavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crescenzio Francesco","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Parciante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2970-9426","authenticated-orcid":false,"given":"Anna","family":"Mestice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-8912","authenticated-orcid":false,"given":"Mario","family":"Delia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-6052","authenticated-orcid":false,"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.06.041_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.06.041_bib0002","first-page":"1","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"issue":"7949","key":"10.1016\/j.jtct.2026.06.041_bib0003","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.041_bib0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/cancers12010185","article-title":"Molecular complexity of diffuse large B-cell lymphoma: can it be a roadmap for precision medicine?","volume":"12","author":"Coccaro","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2026.06.041_bib0005","doi-asserted-by":"crossref","first-page":"102479","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"10.1016\/j.jtct.2026.06.041_bib0006","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1182\/bloodadvances.2025017509","article-title":"The CAR-HEMATOTOX: ready for prime time","volume":"9","author":"Frenking","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.06.041_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.06.041_bib0008","unstructured":"U.S. Food and Drug Administration; Center for Biologics Evaluation and Research. Considerations for the development of chimeric antigen receptor (CAR) T cell products: Guidance for industry. Silver Spring (MD): FDA; 2024. Available from: https:\/\/www.fda.gov\/media\/156896\/"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.041_bib0009","doi-asserted-by":"crossref","first-page":"201099","DOI":"10.1016\/j.omton.2025.201099","article-title":"CAR-T cell exhaustion in B cell lymphoma: current status, mechanisms, and potential solutions","volume":"34","author":"Zhao","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jtct.2026.06.041_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-021-00560-6","article-title":"Insights on droplet digital PCR\u2013based cellular kinetics and biodistribution assay support for CAR-T cell therapy","volume":"23","author":"Sugimoto","year":"2021","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.041_bib0012","doi-asserted-by":"crossref","first-page":"306.e1","DOI":"10.1016\/j.jtct.2023.12.672","article-title":"Digital PCR improves sensitivity and quantification in monitoring CAR-T cells in B cell lymphoma patients","volume":"30","author":"de la Iglesia-San Sebasti\u00e1n","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5644","key":"10.1016\/j.jtct.2026.06.041_bib0013","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science (80-)"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.041_bib0014","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"issue":"5466","key":"10.1016\/j.jtct.2026.06.041_bib0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science (80-)"},{"issue":"227","key":"10.1016\/j.jtct.2026.06.041_bib0016","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.041_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-022-03729-5","article-title":"Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products","volume":"20","author":"Shao","year":"2022","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0018","first-page":"338","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell","volume":"30","author":"Levine","year":"2025","journal-title":"Therapy"},{"issue":"22","key":"10.1016\/j.jtct.2026.06.041_bib0019","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1056\/NEJMe2405538","article-title":"T-cell cancer after CAR T-cell therapy","volume":"390","author":"Mitchell","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.041_bib0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.041_bib0021","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.1007\/s00432-023-04587-4","article-title":"Prognostic value of baseline and early response FDG-PET\/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy","volume":"149","author":"Georgi","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.041_bib0022","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.041_bib0023","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/jcm11061522","article-title":"Value of CT-textural features and volume-based PET parameters in comparison to serologic markers for response prediction in patients with diffuse large B-cell lymphoma undergoing CD19-CAR-T cell therapy","volume":"11","author":"Reinert","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0024","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21941","article-title":"Monitoring CAR T-cells using flow cytometry","volume":"100","author":"Demaret","year":"2021","journal-title":"Cytom Part B \u2013 Clin Cytom"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms23020903","article-title":"Comparison of FACS and PCR for detection of BCMA-CAR-T cells","volume":"23","author":"Reichman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtct.2026.06.041_bib0026","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.omtm.2020.12.002","article-title":"Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay","volume":"20","author":"Davis","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21","key":"10.1016\/j.jtct.2026.06.041_bib0027","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.041_bib0028","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0029","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4155\/bio-2020-0221","article-title":"Considerations in the development and validation of real-time quantitative polymerase chain reaction and its application in regulated bioanalysis to characterize the cellular kinetics of CAR-T products in clinical studies","volume":"13","author":"Yang","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jtct.2026.06.041_bib0031","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8030","key":"10.1016\/j.jtct.2026.06.041_bib0032","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41586-024-07862-7","article-title":"Fate induction in CD8 CAR T cells through asymmetric cell division","volume":"633","author":"Lee","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0033","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Cd4: Cd8+ cart","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.041_bib0034","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR T cells affects in vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.041_bib0035","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.041_bib0036","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.041_bib0037","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.041_bib0038","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.041_bib0039","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41409-023-02016-1","article-title":"CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas","volume":"58","author":"Baur","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.041_bib0040","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1182\/bloodadvances.2023012470","article-title":"Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma","volume":"8","author":"Saldarriaga","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.041_bib0041","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41375-025-02547-0","article-title":"Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma","volume":"39","author":"Dingli","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.06.041_bib0042","first-page":"2786","article-title":"Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed\/refractory multiple myeloma","author":"Chai","year":"2026","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.041_bib0043","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cyto.a.24676","article-title":"Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction","volume":"103","author":"Cheng","year":"2023","journal-title":"Cytometry A"},{"key":"10.1016\/j.jtct.2026.06.041_bib0044","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"issue":"22","key":"10.1016\/j.jtct.2026.06.041_bib0045","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.041_bib0046","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/ijms25052673","article-title":"Unlocking predictive power: quantitative assessment of CAR-T expansion with digital droplet polymerase chain reaction (ddPCR)","volume":"25","author":"Galli","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.041_bib0047","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jtct.2025.01.001","article-title":"Reduced chimeric antigen receptor T cell expansion postinfusion is associated with poor survival in patients with large B cell lymphoma after two or more therapies","volume":"31","author":"Abadir","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.06.041_bib0048","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40262-025-01531-2","article-title":"Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed\/refractory multiple myeloma","volume":"64","author":"Wu","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"7709","key":"10.1016\/j.jtct.2026.06.041_bib0049","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.041_bib0050","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.06.041_bib0051","doi-asserted-by":"crossref","first-page":"1411393","DOI":"10.3389\/fimmu.2024.1411393","article-title":"Engineering strategies to safely drive CAR T-cells into the future","volume":"15","author":"Rossi","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.041_bib0052","doi-asserted-by":"crossref","first-page":"E957","DOI":"10.1097\/HS9.0000000000000957","article-title":"Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients","volume":"7","author":"Panagiota","year":"2023","journal-title":"HemaSphere"},{"issue":"15","key":"10.1016\/j.jtct.2026.06.041_bib0053","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.041_bib0054","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","article-title":"Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment","volume":"6","author":"Teipel","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.041_bib0055","doi-asserted-by":"crossref","first-page":"927.e1","DOI":"10.1016\/j.jtct.2024.06.008","article-title":"Clonal hematopoiesis is associated with severe cytokine release syndrome in patients treated with chimeric antigen receptor T-cell (CART) therapy","volume":"30","author":"Goldsmith","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.041_bib0056","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/bloodadvances.2025015981","article-title":"Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma","volume":"9","author":"Gustine","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.06.041_bib0057","first-page":"rs.3.rs","article-title":"CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias","volume":"21","author":"Hamilton","year":"2025","journal-title":"Res Sq [Preprint]"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.041_bib0058","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3390\/curroncol30010087","article-title":"Fatal progression of mutated TP53-associated clonal hematopoiesis following anti-CD19 CAR-T cell therapy","volume":"30","author":"Eder","year":"2023","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.06.041_bib0059","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"20","key":"10.1016\/j.jtct.2026.06.041_bib0060","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1158\/1078-0432.CCR-25-1587","article-title":"Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy","volume":"31","author":"Avigan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.041_bib0061","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.041_bib0062","doi-asserted-by":"crossref","first-page":"110079","DOI":"10.1016\/j.celrep.2021.110079","article-title":"CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia","volume":"37","author":"Zebley","year":"2021","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.041_bib0063","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.1700559","article-title":"The loss of TET2 promotes CD8+ T cell memory differentiation","volume":"200","author":"Carty","year":"2018","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.041_bib0064","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.06.041_bib0065","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1172\/JCI41991","article-title":"Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice","volume":"120","author":"Stromnes","year":"2010","journal-title":"J Clin Invest"},{"issue":"817","key":"10.1016\/j.jtct.2026.06.041_bib0066","doi-asserted-by":"crossref","first-page":"eadu9790","DOI":"10.1126\/scitranslmed.adu9790","article-title":"CAR T cell-mediated bone marrow inflammation causes hematotoxicity and favors clonal hematopoiesis","volume":"17","author":"Khelil","year":"2025","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.041_bib0067","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","article-title":"Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody","volume":"31","author":"Braun","year":"2025","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.jtct.2026.06.041_bib0068","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","article-title":"Aggressive lymphoma after CD19 CAR T-cell therapy","volume":"391","author":"Kobbe","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jtct.2026.06.041_bib0069","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.041_bib0070","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bjh.70247","article-title":"Position statement from the British Society of Blood and Marrow Transplantation and Cellular Therapy on insertional oncogenesis in gene-engineered advanced cell therapy products for treatment of haematological disorders","volume":"208","author":"Ghorashian","year":"2026","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.jtct.2026.06.041_bib0071","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jtct.2026.06.041_bib0072","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.2020010497","article-title":"The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma","volume":"138","author":"Chihara","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.06.041_bib0073","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.06.041_bib0074","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","article-title":"CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma","volume":"142","author":"Harrison","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.06.041_bib0076","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jtct.2026.06.041_bib0077","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jtct.2026.06.041_bib0078","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.041_bib0079","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.041_bib0080","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMc2504588","article-title":"Targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR T-cell therapy","volume":"393","author":"Aleman","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.06.041_bib0081","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2023-182817","article-title":"C-CAR039, a novel anti-CD20\/CD19 bi-specific CAR T-cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r\/r) B-cell non-Hodgkin lymphoma (B-NHL) in long term follow up","volume":"142","author":"Li","year":"2023","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:56:59Z","timestamp":1791529019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666636726005142"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.041","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}